Anzeige
Mehr »
Mittwoch, 25.03.2026 - Börsentäglich über 12.000 News
+2.000% bisher - kommt jetzt der nächste Antimon-Trade? A2 Gold zündet die nächste Stufe!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3C813 | ISIN: CA68234M2058 | Ticker-Symbol: VF5
Frankfurt
25.03.26 | 08:00
0,100 Euro
-3,40 % -0,004
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ONDINE BIOMEDICAL INC CDIS Chart 1 Jahr
5-Tage-Chart
ONDINE BIOMEDICAL INC CDIS 5-Tage-Chart

Aktueller Chart ONDINE BIOMEDICAL Aktie

Chart vergleichen mit:

Firmenname, WKN, ISIN oder Aktien-Kürzel

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%
Chart-Typ:
Zeitraum:
 
ONDINE BIOMEDICAL INC CDIS-Investoren interessieren sich auch für diese Wertpapiere
Weekly Buzz: Bristol Myers Squibb Wins FDA Nod; EU Okays Johnson & Johnson's AKEEGA; Ipsen Withdraws Tazverik, Day One Biopharmaceuticals AcquiredNEW BRUNSWICK (dpa-AFX) - This week's biotech landscape witnessed key FDA approvals, EU approvals, IND clearances, acquisitions, and clinical trial data readouts across key therapeutic areas...
► Artikel lesen
Servier and Day One Biopharmaceuticals announce acquisition to expand Servier's rare oncology portfolioAcquisition positions Servier as a leader in pediatric low-grade glioma and expands its pipeline with programs targeting adult and pediatric cancers with high unmet needs. Transaction represents...
► Artikel lesen
Day One Biopharmaceuticals, Inc.: Servier and Day One Biopharmaceuticals announce acquisition to expand Servier's rare oncology portfolioAcquisition positions Servier as a leader in pediatric low-grade glioma and expands its pipeline with programs targeting adult and pediatric cancers with high unmet needs Transaction represents total...
► Artikel lesen
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs- CIRRUS-HCM 12-week data of EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) expected in H1 2026 - - Phase 1 healthy adult trial...
► Artikel lesen
Edgewise Therapeutics Provides Corporate Updates and Highlights Priorities for 2026- Advancing robust clinical pipeline of novel therapeutics for muscular dystrophies and serious cardiac conditions - - Presenting at the 44th Annual J.P. Morgan...
► Artikel lesen
Edgewise Therapeutics Announces Completion of the EDG-7500 CIRRUS-HCM Phase 2 Parts B and C and Favorable Interim Safety Results from the Ongoing Part D Study in Hypertrophic Cardiomyopathy- In the CIRRUS-HCM trial, including interim safety results from Part D, EDG-7500 was generally well tolerated; no clinically meaningful reductions in LVEF or LVEF - - On track to deliver...
► Artikel lesen